JP2008542209A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008542209A5 JP2008542209A5 JP2008512656A JP2008512656A JP2008542209A5 JP 2008542209 A5 JP2008542209 A5 JP 2008542209A5 JP 2008512656 A JP2008512656 A JP 2008512656A JP 2008512656 A JP2008512656 A JP 2008512656A JP 2008542209 A5 JP2008542209 A5 JP 2008542209A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- compound according
- benzoic acid
- subject
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 10
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical group S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 claims description 8
- 229910000037 hydrogen sulfide Inorganic materials 0.000 claims description 8
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims description 8
- 229960004963 mesalazine Drugs 0.000 claims description 8
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 7
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 104
- 230000004968 inflammatory condition Effects 0.000 claims 14
- 206010009944 Colon cancer Diseases 0.000 claims 8
- 208000029742 colonic neoplasm Diseases 0.000 claims 8
- 239000005711 Benzoic acid Substances 0.000 claims 6
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 claims 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims 5
- 208000011231 Crohn disease Diseases 0.000 claims 5
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- -1 2-acetylamino-3-mercapto-propionyloxy Chemical group 0.000 claims 3
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 150000008064 anhydrides Chemical class 0.000 claims 3
- DBDMFRBFYLANQK-UHFFFAOYSA-N [4-(5-sulfanylidenedithiol-3-yl)phenyl] 5-amino-2-hydroxybenzoate Chemical compound NC1=CC=C(O)C(C(=O)OC=2C=CC(=CC=2)C=2SSC(=S)C=2)=C1 DBDMFRBFYLANQK-UHFFFAOYSA-N 0.000 claims 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 230000003449 preventive effect Effects 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- CINBWUSRSNZBFY-UHFFFAOYSA-N 2,5-diamino-5-sulfanylidenepentanoic acid Chemical compound OC(=O)C(N)CCC(N)=S CINBWUSRSNZBFY-UHFFFAOYSA-N 0.000 claims 1
- KAANEFXFUHDVPN-UHFFFAOYSA-N 2-[[2-(5-amino-2-hydroxybenzoyl)oxyacetyl]amino]-3-sulfanylpropanoic acid Chemical compound NC1=CC=C(O)C(C(=O)OCC(=O)NC(CS)C(O)=O)=C1 KAANEFXFUHDVPN-UHFFFAOYSA-N 0.000 claims 1
- TXYRSZFMJWFHND-UHFFFAOYSA-N 2-sulfanylethyl hydrogen sulfate Chemical compound OS(=O)(=O)OCCS TXYRSZFMJWFHND-UHFFFAOYSA-N 0.000 claims 1
- MFEKCQPTGSAYKB-UHFFFAOYSA-N 3-[(2-amino-2-sulfanylideneethoxy)carbonylamino]benzoic acid Chemical compound NC(=S)COC(=O)NC1=CC=CC(C(O)=O)=C1 MFEKCQPTGSAYKB-UHFFFAOYSA-N 0.000 claims 1
- QFBHGYAVQZQYMO-UHFFFAOYSA-N 3-[(4-carbamothioylphenoxy)carbonylamino]benzoic acid Chemical compound C1=CC(C(=S)N)=CC=C1OC(=O)NC1=CC=CC(C(O)=O)=C1 QFBHGYAVQZQYMO-UHFFFAOYSA-N 0.000 claims 1
- KEFUFRLCEPVDHV-UHFFFAOYSA-N 3-[(5-amino-1-hydroxy-5-sulfanylidenepentan-2-yl)carbamoylamino]benzoic acid Chemical compound NC(=S)CCC(CO)NC(=O)NC1=CC=CC(C(O)=O)=C1 KEFUFRLCEPVDHV-UHFFFAOYSA-N 0.000 claims 1
- QEIIGNLGMJELAK-UHFFFAOYSA-N 3-[[4-(5-sulfanylidenedithiol-3-yl)phenyl]diazenyl]benzoic acid Chemical compound OC(=O)C1=CC=CC(N=NC=2C=CC(=CC=2)C=2SSC(=S)C=2)=C1 QEIIGNLGMJELAK-UHFFFAOYSA-N 0.000 claims 1
- XFDUHJPVQKIXHO-UHFFFAOYSA-N 3-aminobenzoic acid Chemical compound NC1=CC=CC(C(O)=O)=C1 XFDUHJPVQKIXHO-UHFFFAOYSA-N 0.000 claims 1
- BLINMQRVKJYUFX-UHFFFAOYSA-N 5-[(1-carboxy-2-sulfanylethyl)carbamoyl-methoxycarbonylamino]-2-hydroxybenzoic acid Chemical compound SCC(C(O)=O)NC(=O)N(C(=O)OC)C1=CC=C(O)C(C(O)=O)=C1 BLINMQRVKJYUFX-UHFFFAOYSA-N 0.000 claims 1
- CBFMEZVPXSOKET-UHFFFAOYSA-N 5-[(2,5-diamino-5-sulfanylidenepentanoyl)amino]-2-hydroxybenzoic acid Chemical compound NC(=S)CCC(N)C(=O)NC1=CC=C(O)C(C(O)=O)=C1 CBFMEZVPXSOKET-UHFFFAOYSA-N 0.000 claims 1
- DLINENPDJAWTRW-UHFFFAOYSA-N 5-[(2-acetamido-3-sulfanylpropanoyl)amino]-2-hydroxybenzoic acid Chemical compound CC(=O)NC(CS)C(=O)NC1=CC=C(O)C(C(O)=O)=C1 DLINENPDJAWTRW-UHFFFAOYSA-N 0.000 claims 1
- MZDXTCXUNOBCQO-UHFFFAOYSA-N 5-[(4-amino-1-carboxy-4-sulfanylidenebutyl)diazenyl]-2-hydroxybenzoic acid Chemical compound NC(=S)CCC(C(O)=O)N=NC1=CC=C(O)C(C(O)=O)=C1 MZDXTCXUNOBCQO-UHFFFAOYSA-N 0.000 claims 1
- CRTFCLLAVDRVOO-UHFFFAOYSA-N 5-[[2-[(1-carboxy-2-sulfanylethyl)amino]-2-oxoethyl]diazenyl]-2-hydroxybenzoic acid Chemical compound OC(=O)C(CS)NC(=O)CN=NC1=CC=C(O)C(C(O)=O)=C1 CRTFCLLAVDRVOO-UHFFFAOYSA-N 0.000 claims 1
- UMBFBJOWJCSNKO-UHFFFAOYSA-N 5-amino-2-(2,5-diamino-5-sulfanylidenepentanoyl)oxybenzoic acid Chemical compound NC(=S)CCC(N)C(=O)OC1=CC=C(N)C=C1C(O)=O UMBFBJOWJCSNKO-UHFFFAOYSA-N 0.000 claims 1
- FQGCHJYMDJOHAT-UHFFFAOYSA-N 5-amino-2-(2-amino-2-sulfanylideneethoxy)carbonyloxybenzoic acid Chemical compound NC(=S)COC(=O)OC1=CC=C(N)C=C1C(O)=O FQGCHJYMDJOHAT-UHFFFAOYSA-N 0.000 claims 1
- DOBTUCQCZRTKRD-UHFFFAOYSA-N 5-amino-2-(2-sulfanylethoxysulfonyloxy)benzoic acid Chemical compound NC1=CC=C(OS(=O)(=O)OCCS)C(C(O)=O)=C1 DOBTUCQCZRTKRD-UHFFFAOYSA-N 0.000 claims 1
- YKOVUZBGGQFJOI-UHFFFAOYSA-N 5-amino-2-(4-carbamothioylphenoxy)carbonyloxybenzoic acid Chemical compound C1=CC(C(=S)N)=CC=C1OC(=O)OC1=CC=C(N)C=C1C(O)=O YKOVUZBGGQFJOI-UHFFFAOYSA-N 0.000 claims 1
- HPKZJKJXIKHGRM-UHFFFAOYSA-N 5-amino-2-[(4-amino-1-carboxy-4-sulfanylidenebutyl)carbamoyloxy]benzoic acid Chemical compound NC(=S)CCC(C(O)=O)NC(=O)OC1=CC=C(N)C=C1C(O)=O HPKZJKJXIKHGRM-UHFFFAOYSA-N 0.000 claims 1
- GNYKDUWXFOYQJM-UHFFFAOYSA-N 5-amino-2-[2-[(1-carboxy-2-sulfanylethyl)amino]-2-oxoethoxy]carbonyloxybenzoic acid Chemical compound NC1=CC=C(OC(=O)OCC(=O)NC(CS)C(O)=O)C(C(O)=O)=C1 GNYKDUWXFOYQJM-UHFFFAOYSA-N 0.000 claims 1
- OFFGCRIILKXXJW-UHFFFAOYSA-N 5-amino-2-[4-(5-sulfanylidenedithiol-3-yl)phenoxy]carbonyloxybenzoic acid Chemical compound OC(=O)C1=CC(N)=CC=C1OC(=O)OC1=CC=C(C=2SSC(=S)C=2)C=C1 OFFGCRIILKXXJW-UHFFFAOYSA-N 0.000 claims 1
- 206010017969 Gastrointestinal inflammatory conditions Diseases 0.000 claims 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 1
- OKNZGKUVCKVSKJ-UHFFFAOYSA-N S=C1C=C(SS1)C1=CC=C(OC(=O)NC2=C(C(=O)O)C=CC=C2)C=C1 Chemical compound S=C1C=C(SS1)C1=CC=C(OC(=O)NC2=C(C(=O)O)C=CC=C2)C=C1 OKNZGKUVCKVSKJ-UHFFFAOYSA-N 0.000 claims 1
- 229960004308 acetylcysteine Drugs 0.000 claims 1
- 235000010233 benzoic acid Nutrition 0.000 claims 1
- KBOPZPXVLCULAV-UHFFFAOYSA-M mesalaminate(1-) Chemical compound NC1=CC=C(O)C(C([O-])=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-M 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 239000002253 acid Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 2
- 102000016924 KATP Channels Human genes 0.000 description 2
- 108010053914 KATP Channels Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- RWSOTUBLDIXVET-UHFFFAOYSA-M hydrosulfide Chemical compound [SH-] RWSOTUBLDIXVET-UHFFFAOYSA-M 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 2
- 229960001940 sulfasalazine Drugs 0.000 description 2
- 0 *CCCC(N)=S Chemical compound *CCCC(N)=S 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- DWKPPFQULDPWHX-UHFFFAOYSA-N CC(C(OC)=O)N Chemical compound CC(C(OC)=O)N DWKPPFQULDPWHX-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 208000002389 Pouchitis Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000010282 redox signaling Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- HYHCSLBZRBJJCH-UHFFFAOYSA-M sodium hydrosulfide Chemical compound [Na+].[SH-] HYHCSLBZRBJJCH-UHFFFAOYSA-M 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 230000019086 sulfide ion homeostasis Effects 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CA2005/000819 WO2006125293A1 (en) | 2005-05-27 | 2005-05-27 | Derivatives of 4- or 5-aminosalicylic acid |
| CAPCT/CA2005/000819 | 2005-05-27 | ||
| PCT/CA2006/000484 WO2006125295A1 (en) | 2005-05-27 | 2006-03-31 | Derivatives of 4-or 5-aminosalicylic acid |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008542209A JP2008542209A (ja) | 2008-11-27 |
| JP2008542209A5 true JP2008542209A5 (https=) | 2009-06-18 |
| JP5221341B2 JP5221341B2 (ja) | 2013-06-26 |
Family
ID=37451592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008512656A Expired - Fee Related JP5221341B2 (ja) | 2005-05-27 | 2006-03-31 | ４−または５−アミノサリチル酸誘導体 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7910568B2 (https=) |
| EP (1) | EP1883645B1 (https=) |
| JP (1) | JP5221341B2 (https=) |
| KR (1) | KR101298880B1 (https=) |
| CN (1) | CN101238137B (https=) |
| AT (1) | ATE514704T1 (https=) |
| AU (1) | AU2006251803B2 (https=) |
| BR (3) | BR122019014196B8 (https=) |
| CA (1) | CA2609224C (https=) |
| ES (1) | ES2368650T3 (https=) |
| IL (1) | IL187319A (https=) |
| NO (1) | NO340528B1 (https=) |
| NZ (1) | NZ563354A (https=) |
| RU (1) | RU2414476C2 (https=) |
| UA (1) | UA96264C2 (https=) |
| WO (2) | WO2006125293A1 (https=) |
| ZA (1) | ZA200710472B (https=) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8541398B2 (en) | 2005-05-27 | 2013-09-24 | Antibe Therapeutics Inc. | Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs |
| US7741359B2 (en) * | 2005-05-27 | 2010-06-22 | Antibe Therapeutics Inc. | Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs |
| CN101501018B (zh) * | 2006-07-18 | 2014-08-27 | 安泰碧控股公司 | 非甾体抗炎药的硫化氢衍生物 |
| PT2057139E (pt) * | 2006-07-18 | 2013-12-05 | Antibe Holdings Inc | Derivados de sulfureto de hidrogénio de fármacos antiinflamatórios não esteroidais |
| JP5461390B2 (ja) * | 2007-05-21 | 2014-04-02 | レール・リキード−ソシエテ・アノニム・プール・レテュード・エ・レクスプロワタシオン・デ・プロセデ・ジョルジュ・クロード | 半導体用途のための新規金属前駆体 |
| CN101541780B (zh) * | 2007-06-08 | 2012-12-05 | 成都地奥九泓制药厂 | 贝特羧酸酯类化合物及其制备方法和用途 |
| EP2062578A1 (en) * | 2007-11-12 | 2009-05-27 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Novel use of chemical compounds for the treatment of AIDS |
| ITMI20072429A1 (it) * | 2007-12-24 | 2009-06-25 | Giuliani Int Ltd | Composti per il trattamento selettivo della componente immuno-infiammatoria intestinale della malattia celiaca |
| US8569466B2 (en) * | 2008-09-10 | 2013-10-29 | Nnochiri Ekwuribe | Aromatic carboxylic acid derivatives for treatment and prophylaxis of gastrointestinal diseases including colon cancers |
| CA2827887C (en) | 2011-08-15 | 2020-06-09 | Research Foundation Of The City University Of New York | No- and h2s-releasing compounds |
| WO2014037832A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment of epilepsy and neurological diseases |
| WO2013167985A1 (en) | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological disorders |
| US9399634B2 (en) | 2012-05-07 | 2016-07-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of depression |
| WO2013168021A1 (en) | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders |
| US9434704B2 (en) | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
| WO2013167992A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of inflammatory disorders |
| WO2013168025A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of blood clotting disorders |
| WO2013168023A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of parkinson's disease |
| US9522884B2 (en) | 2012-05-08 | 2016-12-20 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic disorders |
| WO2013167999A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurologic diseases |
| WO2013168002A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological conditions |
| WO2013167997A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
| WO2013168005A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
| WO2013168016A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
| US9273061B2 (en) | 2012-05-10 | 2016-03-01 | Cellix Bio Private Limited | Compositions and methods for the treatment of chronic pain |
| WO2013168000A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of severe pain |
| US9499527B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of familial amyloid polyneuropathy |
| WO2013168012A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
| WO2013168015A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of asthma and allergy |
| WO2013168004A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of fibromyalgia pain |
| US9321775B2 (en) | 2012-05-10 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of moderate to severe pain |
| WO2013168033A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of neurologic diseases |
| WO2013175344A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
| AU2013264820A1 (en) | 2012-05-23 | 2014-11-27 | Cellixbio Private Limited | Compositions and methods for treatment of mucositis |
| NZ701832A (en) * | 2012-05-23 | 2016-08-26 | Cellix Bio Private Ltd | Compositions and methods for treatment of inflammatory bowel disease |
| WO2013175347A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
| JP2015518854A (ja) | 2012-05-23 | 2015-07-06 | セリックスビオ プライヴェート リミテッド | 多発性硬化症の治療のための組成物および方法 |
| US9492409B2 (en) | 2012-05-23 | 2016-11-15 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
| US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| WO2014020480A2 (en) | 2012-08-03 | 2014-02-06 | Mahesh Kandula | Compositions and methods for the treatment migraine and neurologic diseases |
| CN102807557B (zh) * | 2012-08-21 | 2015-02-04 | 苏州大学 | 3h-1,2-二硫环戊烯-3-硫酮类化合物及其应用 |
| WO2014037833A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment inflammation and lipid disorders |
| SG11201407325YA (en) | 2012-09-08 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for treatment of inflammation and lipid disorders |
| AU2014235209B2 (en) * | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
| CN103254257A (zh) * | 2013-04-18 | 2013-08-21 | 山西医科大学 | 一种4-氨基水杨酸糖苷类衍生物及其制备方法 |
| US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
| SG11201509782TA (en) | 2013-06-04 | 2015-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of diabetes and pre-diabetes |
| CN103483214B (zh) * | 2013-06-09 | 2015-04-29 | 西安交通大学 | 一种化合物及其制备方法和抗溃疡性结肠炎用途 |
| US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
| NZ736131A (en) | 2014-09-26 | 2019-04-26 | Cellix Bio Private Ltd | Compositions and methods for the treatment of epilepsy and neurological disorders |
| ES2799309T3 (es) | 2014-09-29 | 2020-12-16 | Cellix Bio Private Ltd | Compuestos y composiciones para el tratamiento de esclerosis múltiple |
| JP6564868B2 (ja) | 2014-10-27 | 2019-08-21 | セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ | 多発性硬化症の治療のための、フマル酸モノメチルエステルとピペラジン又はエチレンジアミンとの３つの成分の塩 |
| US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
| US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
| US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
| US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
| US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
| US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
| WO2016088132A1 (en) | 2014-12-01 | 2016-06-09 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
| US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
| SG11201705524SA (en) | 2015-01-06 | 2017-08-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of inflammation and pain |
| SG11201900588YA (en) * | 2016-08-11 | 2019-02-27 | Cellix Bio Private Ltd | Compositions and methods for the treatment of irritable bowel syndrome |
| CN120682290A (zh) * | 2017-07-04 | 2025-09-23 | 尹图赛利有限公司 | 包含可裂解接头的化合物及其用途 |
| US10100005B1 (en) * | 2017-11-17 | 2018-10-16 | Eclipse Therapeutics, LLC | Mesalazine derivatives |
| KR20220055697A (ko) | 2020-10-27 | 2022-05-04 | 강원대학교산학협력단 | 살리신을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물 |
| CN113398112A (zh) * | 2021-06-17 | 2021-09-17 | 西南医科大学 | FA介导的BBA/CM-β-CD靶向递药系统、制备方法及其应用 |
| CN115960075B (zh) * | 2021-10-08 | 2024-11-08 | 深圳枫语生物医药科技有限公司 | 一种咖啡酸衍生物及其制备方法和应用 |
| CN114605277B (zh) * | 2022-04-18 | 2022-10-11 | 宁波怡和医药科技有限公司 | 一种美沙拉嗪的合成方法 |
| CN116444408B (zh) * | 2023-06-14 | 2023-09-26 | 山东大学 | 一种多靶点型双硫仑衍生物、药物组合物及其抗肿瘤应用 |
| CN117679402A (zh) * | 2024-01-10 | 2024-03-12 | 北京化工大学 | 莱菔素在制备治疗溃疡性结肠炎药物中的应用 |
| WO2025248450A1 (en) * | 2024-05-28 | 2025-12-04 | Antibe Therapeutics, Inc. | H2s-releasing mesalamine analogs |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE900937C (de) * | 1952-05-14 | 1954-01-04 | Dr Bruno Boettcher | Verfahren zur Herstellung schwefelhaltiger organischer Verbindungen |
| BE642496A (https=) * | 1963-01-16 | 1964-07-01 | ||
| US4161550A (en) * | 1977-09-21 | 1979-07-17 | The Procter & Gamble Company | Meat aroma precursor composition |
| JPS57500432A (https=) | 1980-03-20 | 1982-03-11 | ||
| US4412992A (en) * | 1980-07-21 | 1983-11-01 | Biorex Laboratories Limited | 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith |
| US4440763A (en) | 1981-03-18 | 1984-04-03 | Block Drug Company, Inc. | Use of 4-aminosalicyclic acid as an anti-inflammatory agent |
| JPH04154773A (ja) * | 1990-10-15 | 1992-05-27 | Green Cross Corp:The | チアゾール誘導体 |
| US20050090553A1 (en) * | 1992-06-30 | 2005-04-28 | Shapiro Howard K. | Compositions and method for treatment of chronic inflammatory diseases |
| WO1997009329A1 (en) * | 1995-09-08 | 1997-03-13 | J. Uriach & Cia. S.A. | Azo derivatives of 5-aminosalicylic acid for treatment of inflammatory bowel disease |
| SE9700934D0 (sv) * | 1997-03-14 | 1997-03-14 | Astra Ab | New formulation |
| IT1311923B1 (it) * | 1999-04-13 | 2002-03-20 | Nicox Sa | Composti farmaceutici. |
| AU2001279064A1 (en) * | 2000-07-27 | 2002-02-13 | Rutgers, The State University | Therapeutic azo-compounds for drug delivery |
| ATE460394T1 (de) * | 2000-08-29 | 2010-03-15 | Biocon Ltd | 5-asa-derivate mit entzündungshemmender und antibiotischer wirkung und verfahren zur behandlung von krankheiten mit diesen derivaten |
| AU2004314731B2 (en) | 2004-01-20 | 2011-07-07 | The Board Of Regents Of The University Of Oklahoma | Compositions and methods of treatment for inflammatory diseases |
| EP1886681A3 (en) | 2004-10-07 | 2008-11-19 | Sulfidris S.r.l. | 5-(p-hydroxyphenyl)-3H-1,2-dithiol-3-thione valproate ester |
| EP1836160A1 (en) | 2004-12-24 | 2007-09-26 | CTG Pharma S.r.l. | Compounds for treating metabolic syndrome |
| US7498355B2 (en) * | 2005-05-27 | 2009-03-03 | Antibe Therapeutics Inc. | Derivatives of 4- or 5-aminosalicylic acid |
-
2005
- 2005-05-27 WO PCT/CA2005/000819 patent/WO2006125293A1/en not_active Ceased
-
2006
- 2006-03-31 ES ES06721742T patent/ES2368650T3/es not_active Expired - Lifetime
- 2006-03-31 US US11/915,305 patent/US7910568B2/en not_active Expired - Fee Related
- 2006-03-31 BR BR122019014196A patent/BR122019014196B8/pt active IP Right Grant
- 2006-03-31 KR KR1020077030493A patent/KR101298880B1/ko not_active Expired - Fee Related
- 2006-03-31 WO PCT/CA2006/000484 patent/WO2006125295A1/en not_active Ceased
- 2006-03-31 NZ NZ563354A patent/NZ563354A/en not_active IP Right Cessation
- 2006-03-31 AU AU2006251803A patent/AU2006251803B2/en not_active Ceased
- 2006-03-31 EP EP06721742A patent/EP1883645B1/en not_active Expired - Lifetime
- 2006-03-31 UA UAA200714842A patent/UA96264C2/ru unknown
- 2006-03-31 RU RU2007148924/04A patent/RU2414476C2/ru active
- 2006-03-31 ZA ZA200710472A patent/ZA200710472B/xx unknown
- 2006-03-31 CA CA2609224A patent/CA2609224C/en not_active Expired - Lifetime
- 2006-03-31 BR BRPI0605840-0A patent/BRPI0605840A/pt not_active Application Discontinuation
- 2006-03-31 CN CN2006800251569A patent/CN101238137B/zh not_active Expired - Fee Related
- 2006-03-31 JP JP2008512656A patent/JP5221341B2/ja not_active Expired - Fee Related
- 2006-03-31 AT AT06721742T patent/ATE514704T1/de not_active IP Right Cessation
- 2006-03-31 BR BR122019014203A patent/BR122019014203B8/pt active IP Right Grant
-
2007
- 2007-11-12 IL IL187319A patent/IL187319A/en active IP Right Grant
- 2007-12-21 NO NO20076625A patent/NO340528B1/no not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008542209A5 (https=) | ||
| JP5221341B2 (ja) | ４−または５−アミノサリチル酸誘導体 | |
| Bhandari et al. | Design, synthesis and evaluation of antiinflammatory, analgesic and ulcerogenicity studies of novel S-substituted phenacyl-1, 3, 4-oxadiazole-2-thiol and Schiff bases of diclofenac acid as nonulcerogenic derivatives | |
| AU593606B2 (en) | Novel phenolic thioethers and sulphoxides as inhibitors of 5-lipoxygenase | |
| US7741359B2 (en) | Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs | |
| ES2922425T3 (es) | Profármacos de NSAIA con velocidades de penetración en piel y membranas muy elevadas y sus nuevos usos medicinales | |
| JP5408719B2 (ja) | 非ステロイド系抗炎症薬の硫化水素誘導体 | |
| JP4451595B2 (ja) | 炎症ベースの疾患用薬剤としてのニトロ誘導体 | |
| JP2009543813A5 (https=) | ||
| CA2660814C (en) | Positively charged water-soluble prodrugs of aryl- and heteroarylpropionic acids with very fast skin penetration rate | |
| JP2009543811A5 (https=) | ||
| WO2016159577A2 (ko) | 1,2 나프토퀴논 유도체 및 이의 제조방법 | |
| WO2004046094A9 (en) | Histone deacetylase inhibitors | |
| US20070060544A1 (en) | 4-Nitro-2-[(4'-methoxy)-phenoxy]-methanesulfonanilide derivatives and their pharmaceutical use | |
| EP2049482A1 (en) | Positively charged water-soluble prodrugs of aryl- and heteroarylacetic acids with very fast skin penetration rate | |
| Mahdi et al. | Synthesis, characterization and preliminary pharmacological evaluation of new non-steroidal anti-inflammatory pyrazoline derivatives | |
| US20090275539A1 (en) | Nuclear Transcription Factors Regulators | |
| US20090036516A1 (en) | Compounds for treating metabolic syndrome | |
| Yadav et al. | Synthesis of new chemical entities from paracetamol and NSAIDs with improved pharmacodynamic profile | |
| US20070197479A1 (en) | Derivatives of 4- or 5-aminosalicylic acid | |
| US20080207751A1 (en) | Sulindac Derivatives for Treatment of Cancer | |
| TW200407144A (en) | Hydroxamate derivatives of non-steroidal anti-inflammatory drugs | |
| CA3112073A1 (en) | Aromatic compounds and pharmaceutical uses thereof | |
| Halen et al. | Synthesis and Pharmacological Evaluation of Some Dual‐Acting Amino‐alcohol Ester Derivatives of Flurbiprofen and 2‐[1, 1′‐Biphenyl‐4‐yl] acetic Acid: A Potential Approach to Reduce Local Gastrointestinal Toxicity | |
| US8541398B2 (en) | Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs |